In the current episode of “Immuno Oncology Talks”, we discuss the clinical challenges and future perspectives of CAR-T cells with our experts, from the Oslo University Hospital in Norway, Dr Else Marit Inderberg and Dr Sébastien Wälchli. Dr Inderberg is the head of the immunomonitoring at the hospital and has a research focus on novel immunotherapies, and Dr Wälchli is leading the CAR development platform. MAT-BE-2400334 (ver.1.0) 04 2024
All content for Immuno Oncology Talks is the property of Sanofi and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In the current episode of “Immuno Oncology Talks”, we discuss the clinical challenges and future perspectives of CAR-T cells with our experts, from the Oslo University Hospital in Norway, Dr Else Marit Inderberg and Dr Sébastien Wälchli. Dr Inderberg is the head of the immunomonitoring at the hospital and has a research focus on novel immunotherapies, and Dr Wälchli is leading the CAR development platform. MAT-BE-2400334 (ver.1.0) 04 2024
Targeting Neutrophils as effector cells in cancer therapy
Immuno Oncology Talks
25 minutes
2 years ago
Targeting Neutrophils as effector cells in cancer therapy
The fourth episode of “Immuno Oncology Talks”, Professor Marjolein van Egmond from the Amsterdam University Medical Center, in the Netherlands, will shed light on neutrophils as effector cells in cancer therapy. Professor Marjolein van Egmond specializes in the innate immune system and is focusing on elucidating the therapeutic potential of neutrophils in cancer, with a specific interest in IgA and bispecific antibodies to activate the neutrophils. MAT-BE-2200978 (ver. 1.0) 12 2022
Immuno Oncology Talks
In the current episode of “Immuno Oncology Talks”, we discuss the clinical challenges and future perspectives of CAR-T cells with our experts, from the Oslo University Hospital in Norway, Dr Else Marit Inderberg and Dr Sébastien Wälchli. Dr Inderberg is the head of the immunomonitoring at the hospital and has a research focus on novel immunotherapies, and Dr Wälchli is leading the CAR development platform. MAT-BE-2400334 (ver.1.0) 04 2024
